摘要
目的:探讨XRCC1基因多态性与中晚期胃癌新辅助化疗敏感相关性。方法:将77例中晚期胃癌患者随机分为新辅助化疗组(36例)和常规手术对照组(41例),所有患者均行手术治疗,并经术后病理确诊。采用荧光直接测序法测定XRCC1 399位点多态性与中晚期胃癌新辅助化疗疗效的关系。结果:新辅助化疗组肿瘤细胞坏死率(35.60%)明显高于对照组(3.52%)。新辅助化疗组A/A(55.82%)肿瘤细胞坏死率明显高于A/G(32.13%)及G/G(9.17%)的肿瘤细胞坏死率。新辅助化疗组的组织学有效率为41.70%。通过观察化疗前后的CT图片并结合术中探查,新辅助化疗组患者CR 2例(5.60%),PR 15例(41.60%),SD 14例(38.90%),PD 5例(13.90%),总反应率为47.20%。新辅助化疗组根治性手术切除率(80.56%)明显高于对照组(58.54%),P=0.037。结论:中晚期胃癌新辅助化疗组XRCC1基因399位点A/A多态性与肿瘤细胞坏死率存在相关性,可以作为中晚期胃癌新辅助化疗敏感性的基因水平预测指标。
OBJECTIVE:To detect the correlation of XRCC1 gene polymorphism and neoadjuvant chemotherapy sen- sitivity to advanced gastric cancer. METHODS:Totally 77 advanced gastric cancer patients were selected and randomly di- vided into neoadjuvant chemotherapy group (n= 36) and routine procedure control group (n= 41). All the patients re- ceived surgery and diagnosed by post-operative pathology. XRCC1 399 loci polymorphic were detected by fluorescence based direct sequencing neoadjuvant chemotherapy effect. RESULTS: The tumor cell necrosis rate(35.60%) in neoadju- vant chemotherapy group was obviously higher than that in control group(3.52 %). In neoadjuvant chemotherapy group, A/A group (55.82%) tumor cell necrosis rate was obviously higher than that in A/G(32. 13%) and G/G(9. 17%) group. The histological effective rate was 41.70%. Through CT demonstration before and after chemotherapy,combined with surgical exploration,there were CR in 2 patients(5.60%) ,PR in 15 patients(41.60%) ,SD in 14 patients(38.90%), PD in 5 patients(13.90 %) and total response rate was 47.20 %. The resection rate(80.56 % ) in neoadjuvant chemothera- py group was obviously higher than that in control group(58.54% ,P=0. 037). CONCLUSIONS: XRCC1399A/A SNP is related with tumor cell necrosis rate in neoadjuvant chemotherapy group. XRCC1 399A/A SNP can be a genetic predict index to neoadjuvant chemotherapy sensitivity in advanced gastric cancer.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第19期1477-1479,共3页
Chinese Journal of Cancer Prevention and Treatment